Compare DFLI & BRNS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DFLI | BRNS |
|---|---|---|
| Founded | 2020 | 2016 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Electronic Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 49.0M | 55.9M |
| IPO Year | N/A | 2021 |
| Metric | DFLI | BRNS |
|---|---|---|
| Price | $3.38 | $0.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | ★ $22.50 | $4.00 |
| AVG Volume (30 Days) | ★ 725.8K | 47.4K |
| Earning Date | 11-14-2025 | 03-19-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $57,783,000.00 | N/A |
| Revenue This Year | $17.85 | N/A |
| Revenue Next Year | $30.29 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 18.24 | ★ 1766.46 |
| 52 Week Low | $1.50 | $0.64 |
| 52 Week High | $26.20 | $2.92 |
| Indicator | DFLI | BRNS |
|---|---|---|
| Relative Strength Index (RSI) | 48.31 | 45.38 |
| Support Level | $3.50 | $0.71 |
| Resistance Level | $4.55 | $0.75 |
| Average True Range (ATR) | 0.35 | 0.03 |
| MACD | -0.17 | 0.00 |
| Stochastic Oscillator | 5.24 | 20.00 |
Dragonfly Energy Holdings Corp is a manufacturer of non-toxic deep cycle lithium-ion batteries that are designed to displace lead acid batteries in a number of different storage applications and end markets including RV, marine vessel, and solar and off-grid industries, with disruptive solid-state cell technology currently under development. The company's deep cycle lithium iron phosphate ("LFP") batteries provide numerous advantages compared to incumbent products, such as lead-acid batteries. LFP batteries are non-toxic and environmentally friendly, do not rely on scarce or controversial metals, and are a cost-effective storage solution.
Barinthus Biotherapeutics PLC is a clinical-stage biopharmaceutical company developing novel T-cell immunotherapeutics that guide the immune system to overcome chronic infectious diseases, autoimmunity, and cancer. The company operates as one segment, the research and development of immunotherapies and vaccines.